The Food and Drug Administration is expected to grant full approval to the Alzheimer’s drug lecanemab by July 6. But access to the drug may still be limited.
(Image credit: National Institute on Aging, National Institutes of Health.)
The Food and Drug Administration is expected to grant full approval to the Alzheimer’s drug lecanemab by July 6. But access to the drug may still be limited.
(Image credit: National Institute on Aging, National Institutes of Health.)